Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.
Single kit consolidates three critical newborn screening panels for hospital labs
The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.
Early detection window determines treatment outcomes for rare genetic disorders
SMA is caused by homozygous deletions of the SMN1 exon 7 gene and leads to progressive nerve cell degeneration; detecting it before symptoms appear allows clinicians to initiate targeted therapy that can halt nerve damage and preserve normal growth milestones. SCID, historically termed "bubble boy disease," leaves infants without functioning T cells and is fatal within the first one to two years of life without intervention such as bone marrow transplants performed before infections take hold. SCD, driven by a mutation in the HBB gene, causes red blood cells to become rigid and sickle-shaped; early detection enables preventive penicillin treatment and specialized immunizations that lower infant mortality risk.
TIB MOLBIOL CEO frames test as expansion of Roche's early diagnostics portfolio
Marcus Droege, CEO of TIB MOLBIOL, said catching these diseases before symptoms appear determines whether a child thrives or faces lifelong disability, and that the compliant screening tools aim to prevent delayed diagnoses across European laboratories.
Test positions as first-tier trigger within Roche's integrated diagnostics-to-therapy model
The kit functions as an initial screening trigger that feeds into immediate follow-up testing and therapeutic intervention pathways, reflecting Roche's broader strategy of linking diagnostics directly to treatment decisions across its Diagnostics and Pharmaceutical divisions.